

Research

Open Access

## The reliability and validity of a Japanese version of symptom checklist 90 revised

Mitsunao Tomioka\*<sup>1</sup>, Midori Shimura<sup>2</sup>, Mikio Hidaka<sup>3</sup> and Chiharu Kubo<sup>1</sup>

Address: <sup>1</sup>Department of Psychosomatic Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, 812-8582, Japan, <sup>2</sup>Karibe CLINIC, SOTSU BLD. 2F, 1-3 Honmachi, Naka-ku, Yokohama City, 231-0005, Japan and <sup>3</sup>Faculty of Literature, Kurume University, 1635 Mii-machi, Kurume City, Fukuoka Prefecture, 839-8502, Japan

Email: Mitsunao Tomioka\* - mi-tomi@med.kyushu-u.ac.jp; Midori Shimura - tmidori-kyu@umin.ac.jp; Mikio Hidaka - hidaka\_mikio@kurume-u.ac.jp; Chiharu Kubo - ckubo@med.kyushu-u.ac.jp

\* Corresponding author

Published: 28 October 2008

Received: 9 June 2008

*BioPsychoSocial Medicine* 2008, **2**:19 doi:10.1186/1751-0759-2-19

Accepted: 28 October 2008

This article is available from: <http://www.bpsmedicine.com/content/2/1/19>

© 2008 Tomioka et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Objective:** To examine the validity and reliability of a Japanese version of the Symptom Checklist 90 Revised (SCL-90-R (J)).

**Methods:** The English SCL-90-R was translated to Japanese and the Japanese version confirmed by back-translation. To determine the factor validity and internal consistency of the nine primary subscales, 460 people from the community completed SCL-90-R(J). Test-retest reliability was examined for 104 outpatients and 124 healthy undergraduate students. The convergent-discriminant validity was determined for 80 inpatients who replied to both SCL-90-R(J) and the Minnesota Multiphasic Personality Inventory (MMPI).

**Results:** The correlation coefficients between the nine primary subscales and items were .26 to .78. Cronbach's alpha coefficients were from .76 (Phobic Anxiety) to .86 (Interpersonal Sensitivity). Pearson's correlation coefficients between test-retest scores were from .81 (Psychoticism) to .90 (Somatization) for the outpatients and were from .64 (Phobic Anxiety) to .78 (Paranoid Ideation) for the students. Each of the nine primary subscales correlated well with their corresponding constructs in the MMPI.

**Conclusion:** We confirmed the validity and reliability of SCL-90-R(J) for the measurement of individual distress. The nine primary subscales were consistent with the items of the original English version.

### Background

The Symptom Checklist 90 Revised (SCL-90-R) developed by L.R. Derogatis [1] has been widely used as a clinical assessment and research tool in many countries and is cited in many articles. The scale can assess nine primary psychological symptoms as follows: Somatization (SOM), Obsessive-Compulsive (O-C), Interpersonal Sensitivity (INT), Depression (DEP), Anxiety (ANX), Hostility

(HOS), Phobic Anxiety (PHOB), Paranoid Ideation (PAR), and Psychoticism (PSY).

Although this scale was developed in the late 1970's [2,3], it can still be helpful for understanding psychiatric diseases as classified in the latest version of the diagnostic criteria of DSM-IV[4] and ICD-10 [5].

Many studies have reported that a patient presenting one functional somatic disorder also has symptoms related to psychiatric disorders. For example, Juang et al. [6] reported comorbidity of depressive and anxiety disorders in chronic headache. Seventy-eight percent of patients with migraine had psychiatric comorbidity, including major depression (57%), dysthymia (11%), panic disorder (30%), and generalized anxiety disorder (8%). Sixty four percent of patients with chronic tension-type headache had psychiatric comorbidity, including major depression (51%), dysthymia (8%), and panic disorder (22%). Comorbidity of major depression and panic disorder has often been reported [7,8].

It has been shown that some medicines are effective against multiple psychiatric diseases. For example, selective serotonin reuptake inhibitors (SSRI) are antidepressants that can also be effective against obsessive-compulsive disorder [9], panic disorder [10] and social anxiety disorder [11].

Multi-dimensional assessment tools for psychiatric conditions are needed for the diagnosis of patients in psychosomatic or psychiatric settings.

The only inventory that includes most aspects of emotional disturbances within a comprehensive classification of psychiatric diseases in Japan is the Minnesota Multiphasic Personality Inventory (MMPI)[12]. However, this scale can become a considerable burden to patients because there are a great many questions. More compact scales for measuring multiple psychiatric dimensions are needed.

In this paper we report the development of a Japanese version of SCL-90-R (SCL-90-R(J)). In study 1 the original English version of the SCL-90-R was translated into Japanese and factorial validity and internal consistency were calculated to confirm reliability. Study 2 was done to determine the test-retest reliability of the SCL-90-R(J) by testing psychosomatic medicine outpatients and healthy persons. The aim of study 3 was to investigate the relationship between SCL-90-R(J) and existing scales currently used to measure psychological symptoms in Japan. This investigation was done to show the convergent-discriminant validity of the primary nine subscales of SCL-90-R(J).

## Methods

### Subjects

The SCL-90-R(J) was distributed to 1,200 people living in the suburbs of Fukuoka City who reported for a free medical examination given by the municipal government. The completed forms were returned by mail. Available for analysis were 460 complete forms of 507 (42%) residents

who replied (143 men, average age 59.6 years, and 317 women, average age 50.9 years) in study 1.

118 patients visiting the Department of Psychosomatic Medicine at Kyushu University Hospital who gave informed consent to the study and were given guarantees of protection of private data in the possession their doctor. The SCL-90-R(J) was administered at one visit, and a retest was administered at the next visit. Available for analysis were 104 inventories completed within 35 days (34 men, average age 39.4 years, and 70 women, average age 40.0 years) in study 2. As for the primary diseases of 104 patients, 70.2% were mental diseases and 29.8% were physical diseases. When classified by the mental diseases mentioned in the patients' medical record, 40.4% were diseases related to depression, including diagnosis of depression, neurotic depression, dysthymic disorder. 22.1% were diseases related to anxiety, including anxiety disorder, panic disorder, posttraumatic stress disorder (PTSD), and anxiety neurosis. 4.8% were somatoform disorders, including pain disorder, body dysmorphic disorder and psychogenic aphonia. Two patients had eating disorders and one patient had sleep disorder. As for physical diseases, 13.5% were vegetative syndrome, 6.7% were irritable bowel syndrome, and 2.9% were bronchial asthma. Atopic dermatitis and hyperventilation syndrome were 1.9% each. Functional dyspepsia, hypertension and combined headache were suffered by one patient each.

In study 2, also analyzed were the SCL-90-R(J) test/retest results of 124 healthy undergraduate students (28 men, average age 19.3 years, and 96 women, average age 19.1 years) who attended a psychological guidance lecture at a university in Fukuoka prefecture. The period between test and retest was a week.

Eighty-seven inpatients at Kyushu University Hospital Department of Psychosomatic Medicine replied to the SCL-90-R(J). Of these patients, the results of 80 who replied to both the SCL-90-R(J) and MMPI were analyzed in study 3 (26 males, mean age 37.8 years (SD = 11.7), and 54 females, mean age 33.0 years (SD = 16.1)). Five of eighty patients were overlapped with outpatients who were employed for test/retest examination. As for the primary diseases of 80 patients, 70% were mental diseases and 30% were physical diseases. As classified by DSM-IV, 26.3% were depressive disorders, 21.3% were eating disorders, 11.3% were anxiety disorders, 5.0% were somatoform disorders, 3.8% were adjustment disorders and 2.5% were sleep disorders. As for physical diseases, 16.3% (N = 13) were diabetes mellitus (DM). Ten diabetics were Type 1 DM, and all patients had eating disorders. 3.8% had bronchial asthma and 2.5% had irritable bowel syndrome. Atopic dermatitis, lactose intolerance, cough variant asthma, Crohn's disease, spasmodic torticollis, and

chronic fatigue syndrome were experienced by one patient each.

### **SCL-90-R(J)**

Permission was obtained from the copyright holder to translate the original version of SCL-90-R to Japanese. The translation to Japanese was done by two psychologists. The Japanese version was then back-translated to check for correspondence with the English version. The respondents were asked to describe how much each of 90 problems had distressed or bothered them in the past seven days, including that day. The descriptors were as follows: not at all (0), a little bit (1), moderately (2), quite a bit (3), extremely (4).

### **MMPI**

The MMPI is often used in Japan to assess the psychological state and is commonly used in other countries. Studies of the reliability and validity of this scale have been reported in many articles. To validate the SCL-90-R(J), not only the 10 standard clinical scales (C), but also Wiggins [13] content scales (W) and Tryon's [14] cluster scales (T) were scored.

### **Data analysis**

The Statistical Analysis System (SAS) was used for data analysis. In study 1, confirmative factor analysis was done by the Calis Procedure for covariance structure analysis. Cronbach's alpha coefficients were calculated by Corr Procedure to examine the internal consistencies of each of the nine subscales. In study 2, Pearson's correlation coefficients between the first and second test administrations were calculated using the Corr Procedure to examine the test-retest reliability. In study 3, Pearson's correlation coefficients between subscale scores of SCL-90-R(J) and MMPI scores were calculated.

## **Results**

### **Factorial validity and internal consistency (Study 1)**

The results of confirmative factor analysis are shown in Figure 1. The analysis was done for each of the nine factors. All values of the goodness of fit index (GFI) and adjusted GFI for the nine primary symptoms were over .90. Except for two items on SOM and two items on DEP, the correlation coefficients between each factor and item were over .35.

Cronbach's alpha coefficients were .76 (PHOB) to .86 (INT)(Table 1).

### **Test/retest reliability (Study 2)**

Correlations between test and retest were calculated for outpatients and students (Table 2). Pearson's correlation coefficients were .81 (PSY) to .90 (SOM) for the outpatients and .64 (PHOB) to .78 (PAR) for the student group.

### **Convergent-discriminant validation (Study 3)**

Pearson's product-moment correlation coefficients were calculated between the nine primary subscales of SCL-90-R(J) and the multidimensional subscale of MMPI (Table 2).

The SOM scale showed high correlations with Body Symptoms (T) and Hypochondriasis (C). The SOM scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Masculinity-Femininity (C), Social Introversion (C), Social Maladjustment (W), Feminine Interest (W) and Religious Fundamentalism (W).

The O-C scale showed high correlations with Psychasthenia (C), Tension (T), and Autism (T). The O-C scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Hysteria (C), Masculinity-Femininity (C) and Feminine Interest (W).

The INT scale showed high correlations with Poor Morale (W), Psychasthenia (C), and Depression (W, T). The INT scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Hysteria (C), Masculinity-Femininity (C), Feminine Interest (W) and Religious Fundamentalism (W).


The DEP scale showed high correlations with Psychasthenia (C), Depression (W, T), and Tension (T). The DEP scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Hysteria (C), Masculinity-Femininity (C), Social Maladjustment, Feminine Interest (W) and Religious Fundamentalism (W).

The ANX scale showed high correlations with Tension (T), Psychasthenia (C), and Phobia (W). The ANX scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Masculinity-Femininity (C), Feminine Interest (W) and Religious Fundamentalism (W).

The HOS scale showed high correlations with Manifest Hostility (W), Suspicion and Mistrust (T), and Resentment and Aggression (T). The HOS scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Hysteria (C), Masculinity-Femininity (C), Feminine Interest (W) and Religious Fundamentalism (W).

The PHOB scale showed high correlations with Psychoticism (W), Tension (T), and Phobias (W). The PHOB scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Hysteria (C), Masculinity-Femininity (C), Social Introversion (C, T), Social Maladjustment (W), Feminine Interest (W), Religious Fundamentalism (W) and Family Problems (W).

The PAR scale showed high correlations with Psychoticism (W), Schizophrenia (C), and Suspicion and Mistrust



**Figure 1**  
**Confirmative factor analysis of the nine primary symptom constructs of SCL-90-R(J).** Numbers in boxes accord with the item number of SCL-90-R(J), please see references [1] and [3]. \*Goodness of Fit Index(GFI), \*\*Adjusted GFI(AGFI).

(T). The PAR scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Depression (C), Hysteria (C), Masculinity-Femininity (C) and Feminine Interest (W).

The PSY scale showed high correlations with Psychoticism (W), Suspicion and Mistrust (T), and Schizophrenia (C). The PSY scale showed correlation coefficients lower than 0.20 ( $p > .05$ ) with Depression (C), Hysteria (C), Masculinity-Femininity (C), Social Maladjustment (W), Feminine Interest (W) and Religious Fundamentalism (W).

**Gender differences**

The scores of the nine subscales for all subjects of this study are displayed in Table 3. Gender differences are also examined in this table. In the community sample, gender differences were found in O-C ( $t(458) = 2.32, p = .020$ ) and PSY ( $t(241) = 2.58, p = .010$ ). In the student sample, gender difference was found in PAR ( $t(122) = 2.08, p = .040$ ). For outpatients, gender differences were found in SOM ( $t(102) = 2.35, p = .020$ ), O-C ( $t(102) = 2.09, p = .039$ ), HOS ( $t(95.6) = 2.53, p = .013$ ) and PAR ( $t(102) = 2.24, p = .027$ ). For inpatients, no gender difference was found among the nine subscales.

**Table 1: Internal consistency and test-retest reliability coefficients of SCL-90-R(J)**

	Internal Consistency (coefficient $\alpha$ )		Test-Retest (Pearson's $r$ )	
	Community N = 460	Outpatients N = 104	Students N = 124	
Somatization	.81	.90*	.73*	
Obsessive-Compulsive	.85	.85*	.74*	
Inter personal Sensitivity	.86	.88*	.76*	
Depression	.85	.86*	.76*	
Anxiety	.79	.88*	.73*	
Hostility	.79	.82*	.67*	
Phobic Anxiety	.76	.88*	.64*	
Paranoid Ideation	.79	.83*	.78*	
Psychoticism	.83	.81*	.75*	

\*P < .0001

**Discussion**

**The validity and reliability of SCL-90-R(J)**

We examined the validity and reliability of SCL-90-R(J) for use as a psychometric scale.

SCL-90-R(J) was consistent with the nine primary scales of the original version (Study 1). The data showed that each subscale consisted of items similar enough to the English version that each scale had sufficient internal consistency, indicating its reliability for psychometric testing.

Test-retest reliability was sufficient for the outpatient group. The student group indicated moderate but lower reliability coefficients than the outpatient group (Study 2). The students may have responded according to their mood at the time they filled out the questionnaire rather than to their symptoms, while the patients responded to their symptoms. Because the retest was done by the students at a shorter interval than the patients, the results for the students were of higher reliability than those of the patients. The results were the reverse to our expectations, suggesting that this scale will show a superior performance when used for patients than for healthy persons such as students.

Convergent-discriminant validation demonstrates that measures of interest show strong correlations with independent measures of the same construct and show weak or no correlation with measures of dissimilar constructs. The primary nine subscales of SCL-90-R(J) were strongly correlated with the MMPI subscales of the same or similar construct (Study 3). In addition, dissimilar subscales of MMPI had lower correlation with the SCL-90-R(J) subscales. These results also suggest that the SCL-90-R(J) has convergent and discriminant validity and that the scale is able to assess the constructs that it is intended to measure.

Because we translated the English checklist into Japanese, it was possible that an individual item had a weak rela-

tionship with the subscale in the original version. First, we examined whether or not the nine primary scales of the Japanese version consisted of items the same as the original version (study 1). Confirmative factor analysis showed that almost all items highly correlated with each factor (symptoms) contained in the items in the original version. The data showed that our nine subscales of the Japanese version consisted of the same items as in the English original version. Confirmative factor analysis also demonstrated that each factor had high validation.

Research that would benefit from the use of SCL-90-R(J) includes comparative cross-cultural studies. Several studies have been published that have compared the psychopathology between countries using the SCL-90-R [15,16]. These studies need to be consistent in their use of the same scale from the same items. Our version has this necessary condition with good validation.

Convergent-discriminant validation was demonstrated by contrasting the subscale scores of SCL-90-R(J) with scores from the MMPI. As summarized in Table 2, nine subscales were consistent with the corresponding scales from MMPI. The tendency of the correlation coefficients was similar to the data of Derogatis et al. [17]. In their article, they reported that O-C was not well correlated with MMPI constructs because there was no directly comparable scale on the MMPI. Although this was not changed essentially in our design, the O-C subscale had a moderate relationship with the subscale from MMPI, which would explain the clinical symptoms of obsessive-compulsive disorder in our results.

SCL-90-R is a good tool for researching individual psychological distress. Because this psychological scale can evaluate multidimensional psychopathological aspects simultaneously, it is effective as a screening test for medical examination and treatment. It is also effective for an effect judgment of drug efficacy, such as SSRI against anx-

**Table 2: Correlations between SCL-90-R(J) primary symptom dimensions and MMPI Clinical(C), Wiggins(W), and Tryon-Stein-Chu (T) scales**

Symptom	Correlation <sup>1)</sup>	Symptom	Correlation <sup>1)</sup>
<b>Somatization</b>		Phobia (W)	.63*
Body Symptoms (T)	.74*	Schizophrenia (C)	.60*
Hypochondriasis (C)	.70*	Psychoticism (W)	.60*
Organic Symptoms (W)	.70*	Autism (T)	.58*
Poor Health (W)	.56*	Depression (W)	.57*
		Organic Symptoms (W)	.56*
<b>Obsessive-Compulsive</b>		Poor Morale (W)	.54*
Psychasthenia(C)	.68*	Depression (T)	.52*
Tension (T)	.68*	Hypochondriasis (C)	.51*
Autism (T)	.67*		
Schizophrenia (C)	.65*	<b>Hostility</b>	
Depression (W)	.61*	Manifest Hostility (W)	.67*
Poor Morale (W)	.61*	Suspicion & Mistrust (T)	.61*
Psychoticism (W)	.60*	Resentment & Aggression (T)	.59*
Organic Symptoms (W)	.60*	Depression (W)	.57*
Body Symptoms (T)	.57*	Psychoticism (W)	.57*
Phobias (W)	.56*	Tension (T)	.57*
Depression (T)	.56*	Schizophrenia (C)	.55*
Resentment & Aggression (T)	.55*	Depression (T)	.55*
Hypochondriasis (C)	.52*	Poor Morale (W)	.54*
Manifest Hostility (W)	.51*	Psychasthenia (C)	.53*
Hypomania (W)	.51*		
		<b>Phobic Anxiety</b>	
<b>Interpersonal Sensitivity</b>		Psychoticism (W)	.57*
Poor Morale (W)	.72*	Tension (T)	.55*
Psychasthenia(C)	.70*	Phobias (W)	.52*
Depression (W)	.68*	Depression (W)	.51*
Depression (T)	.68*	Schizophrenia (C)	.50*
Psychoticism (W)	.65*	Suspicion & Mistrust (T)	.50*
Suspicion & Mistrust (T)	.65*		
Schizophrenia (C)	.64*	<b>Paranoid Ideation</b>	
Tension (T)	.63*	Psychoticism (W)	.62*
Autism (T)	.62*	Schizophrenia (C)	.61*
Manifest Hostility (W)	.59*	Suspicion & Mistrust (T)	.61*
Resentment & Aggression (T)	.58*	Autism (T)	.59*
Phobias (W)	.54*	Psychasthenia (C)	.57*
		Depression (W)	.56*
<b>Depression</b>		Poor Morale (W)	.56*
Psychasthenia (C)	.78*	Manifest Hostility (W)	.53*
Depression (W)	.76*	Depression (T)	.53*
Depression (T)	.71*	Resentment & Aggression (T)	.52*
Tension (T)	.71*	Authority Conflict (W)	.51*
Schizophrenia (C)	.70*	Tension (T)	.51*
Poor Morale (W)	.70*	Hypomania (W)	.50*
Autism (T)	.64*		
Psychoticism (W)	.62*	<b>Psychoticism</b>	
Resentment & Aggression (T)	.60*	Psychoticism (W)	.69*
Phobias (W)	.59*	Suspicion & Mistrust (T)	.67*
Body Symptoms (T)	.58*	Schizophrenia (C)	.66*
Organic Symptoms (W)	.54*	Autism (T)	.65*
Manifest Hostility (W)	.54*	Psychasthenia (C)	.64*
Suspicion & Mistrust (T)	.54*	Depression (W)	.64*
Hypochondriasis (C)	.52*	Manifest Hostility (W)	.61*
Paranoia (C)	.51*	Tension (T)	.59*
Psychopathic Deviate (C)	.50*	Poor Morale (W)	.58*
		Resentment & Aggression (T)	.58*
<b>Anxiety</b>		Depression (T)	.55*
Tension (T)	.71*	Hypomania (W)	.51*
Psychasthenia (C)	.66*	Hypomania (C)	.50*

<sup>1)</sup> Displayed correlation coefficient was .50 or more. N = 80. \*p < 0.0001

**Table 3: The basic data and gender differences of the nine primary scales for community, student, out patient, and inpatient samples<sup>1)</sup>**

	SOM	O-C	INT	DEP	ANX	HOS	PHOB	PAR	PSY
<b>Community samples</b>									
All (N = 460)	.63 (.48)	.72 (.56)	.56 (.52)	.73 (.53)	.38 (.39)	.47 (.50)	.16 (.30)	.52 (.53)	.28 (.38)
Men (N = 143)	.64 (.50)	.81 (.59)	.54 (.49)	.75 (.49)	.43 (.41)	.52 (.50)	.16 (.32)	.59 (.55)	.36 (.42)
Women (N = 317)	.63 (.47)	.68 (.55)	.58 (.54)	.73 (.55)	.36 (.38)	.45 (.51)	.16 (.29)	.49 (.52)	.25 (.36)
p <sup>2)</sup>	n s	.020	n s	n s	n s	n s	n s	n s	.010
<b>Undergraduate students</b>									
All (N = 124)	.71 (.58)	.99 (.63)	.82 (.68)	.95 (.69)	.68 (.62)	.74 (.68)	.30 (.45)	.65 (.68)	.40 (.53)
Men (N = 28)	.66 (.47)	.91 (.59)	.84 (.67)	.88 (.67)	.54 (.48)	.78 (.67)	.27 (.43)	.88 (.75)	.46 (.57)
Women (N = 96)	.73 (.61)	1.02 (.64)	.82 (.69)	.97 (.70)	.72 (.65)	.72 (.69)	.31 (.46)	.58 (.64)	.38 (.52)
p <sup>2)</sup>	ns	ns	ns	ns	ns	ns	ns	.040	ns
<b>Outpatients</b>									
All (N = 104)	1.14 (.86)	1.28 (.91)	1.13 (.90)	1.45 (.93)	1.04 (.88)	.85 (.80)	.75 (.85)	.92 (.85)	.65 (.63)
Men (N = 34)	.86 (.74)	1.02 (.87)	.89 (.92)	1.19 (.95)	0.84 (.79)	.61 (.55)	.57 (.81)	.66 (.75)	.51 (.61)
Women (N = 70)	1.27 (.89)	1.41 (.90)	1.25 (.87)	1.57 (.91)	1.14 (.90)	.97 (.88)	.83 (.87)	1.05 (.87)	.72 (.63)
p <sup>2)</sup>	.020	.039	n s	n s	n s	.013	n s	.027	n s
<b>Inpatients</b>									
All (N = 80)	1.05 (.75)	1.29 (.94)	1.14 (.89)	1.60 (.96)	1.03 (.92)	.79 (.92)	.69 (.77)	.94 (.92)	.86 (.82)
Men (N = 26)	1.07 (.73)	1.28 (.94)	1.13 (.92)	1.54 (.92)	1.03 (.87)	.87 (.94)	.71 (.68)	1.04 (.95)	.83 (.89)
Women (N = 54)	1.04 (.76)	1.30 (.95)	1.14 (.89)	1.63 (.99)	1.03 (.95)	.75 (.91)	.68 (.82)	.90 (.91)	.88 (.80)
p <sup>2)</sup>	n s	n s	n s	n s	n s	n s	n s	n s	n s

SOM:Somatization, O-C: Obsessive-Compulsive, INT: Interpersonal Sensitivity, DEP: Depression, ANX: Anxiety, HOS: Hostility, PHOB: Phobic Anxiety, PAR: Paranoid Ideation, PSY: Psychoticism.

<sup>1)</sup> Means (SD)

<sup>2)</sup>The results of t-test on gender differences (men vs women). ns: none significance

ity symptoms [10,11] as well as a depressive mood [18,19]. For example, co-morbidity of major depression and panic disorder has often been reported [7,8], which indicates that SCL-90-R(J) is suitable for the evaluation of patients having such plural diseases. This scale would also be useful for researching the correlation between physical diseases and psychological dysfunction. Mikocka-Walus et al. [20] used this scale to examine the relationship between mental distress and relapse in patients with diseases of the digestive tract.

**Gender differences**

Gender differences in SCL-90-R have been reported [21-24]. Previous articles reported that there was a tendency toward higher scores for females than males on the nine subscales. Most of the gender differences on the nine subscales were statistically significant. The trend was particularly notable for the outpatient sample of this study. But, the gender differences in this study were small when compared with previous studies. There were no significant differences in any of the subscales in the inpatient sample. Though this may be characteristic of Japan, further research to examine a larger sample and data from many institutions will be necessary.

**Limitations of this study**

This study has several limitations. We did not gather the data of psychiatric patients in this study. Data collection

for a group of psychiatric patients will be necessary in future study. When a cut-off point is set, utility is high for clinical application.

Also, our data was collected in only one area of Japan. This might include the possibility of local bias. Future research will include comparative studies of the data from several Japanese areas.

**Conclusion**

We examined the validity and reliability of SCL-90-R(J). Almost of all of the correlation coefficients between the nine primary subscales and items were over .35. Cronbach's alpha coefficients were from .76 (Phobic Anxiety) to .86 (Interpersonal Sensitivity). Pearson's correlation coefficients between test-retest scores were from .81 (Psychoticism) to .90 (Somatization) for the outpatients and were from .64 (Phobic Anxiety) to .78 (Paranoid Ideation) for the students. Each of the nine primary subscales correlated well with their corresponding constructs in the MMPI. We confirmed the validity and reliability of SCL-90-R(J) for the measurement of individual distress. Because the nine primary subscales were consistent with the items of the original English version, this SCL-90-R(J) will be useful for comparative cross-culture study. Also, this psychological scale can evaluate multidimensional psychopathological aspects simultaneously, which makes it useful as a screening test for medical examination and

treatment. For example, it will be useful for judging drug efficacy, such as SSRI for anxiety and depression.

### Competing interests

This study was supported by a grant from Smoking Research Foundation.

### Authors' contributions

MT conceptualized and designed the study, collected the data, performed analysis and interpreted the data, and drafted the manuscript. MS designed the study and translated the SCL-90-R to Japanese. MH collected the data. CK supervised the design of the study and the writing of the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

We gratefully thank the doctors of department of psychosomatic medicine, Kyusyu University Hospital for introduced their patients to us.

### References

- Derogatis LR: *SCL-90-R: Administration, Scoring, and Procedures Manual* Third edition. Minneapolis: National Computer Systems, Inc; 1994.
- Derogatis LR, Cleary PA: **Factorial invariance across gender for the primary symptom dimension of the SCL-90.** *Br J Soc Clin Psychol* 1977, **16**:347-356.
- Derogatis LR, Cleary PA: **Confirmation of the dimensional structure of the SCL-90; A study in construct validation.** *J Clin Psychol* 1977, **33**:981-989.
- American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*. Washington D.C 4th edition. 1994.
- World Health Organization: *International Statistical Classification of Diseases and Related Health Problems, 10th Revision*. Geneva 1992.
- Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP: **Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtype.** *Headache* 2000, **40**:818-823.
- Johnson MR, Lydiard RB: **1998 Comorbidity of major depression and panic disorder.** *J Clin Psychol* 1998, **54**:201-210.
- Biederman J, Petty C, Faraone SV, Hirshfeld-Becker D, Pollack MH, Henin A, Gilbert J, Rosenbaum JF: **Moderating effects of major depression on patterns of comorbidity in patients with panic disorder.** *Psychiatry Res* 2004, **126**:143-149.
- Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT: **Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.** *J Am Acad Child Adolesc Psychiatry* 2001, **40**:222-229.
- Black DW, Wesner R, Bowers W, Gabel J: **A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.** *Arch Gen Psychiatry* 1993, **50**:44-50.
- Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, Walker JR: **Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.** *J Clin Psychopharmacol* 1996, **16**:218-222.
- Friedman AF, Webb JT, Lewak R: **Psychological assessment with the MMPI.** New Jersey: Lawrence Erlbaum Associates, Inc; 1989.
- Wiggins JS: **Substantive dimension of self-report in the MMPI item pool.** *Volume 80.* Psychological Monographs: General and Applied; 1966:1-42. Whole No.630
- Tryon RC: **Unrestricted cluster and factor analysis with application to the MMPI and Holzinger-Harman problems.** *Multivariate Behav Res* 1966, **1**:229-244.
- Barker-Collo SL: **Culture and validity of the Symptom Checklist-90-Revised and Profile of Mood State in a New Zealand student sample.** *Cultural Diversity and Ethnic Minority Psychology* 2003, **9**:185-196.
- Hendriks VM, Steer RA, Platt JJ, Metzger DS: **Psychopathology in Dutch and American heroin addicts.** *Int J addict* 1990, **25**:1051-1063.
- Derogatis LR, Rickels K, Rock A: **The SCL-90 and the MMPI: A step in the validation of a new self report scale.** *Brit J Psychiat* 1976, **128**:280-289.
- Conti L, Dell'Osso L, Re F, Musetti L, Cassano GB: **Fluvoxamine maleate: double-blind clinical trial vs. placebo in hospitalized depressed patients.** *Curr Ther Res* 1988, **43**:468-480.
- Porro V, Fiorenzoni S, Menga C, De Cristofaro A, Bertolino A: **Single-blind comparison of the efficacy of fluvoxamine versus placebo in patients with depressive syndrome.** *Curr Ther Res* 1988, **43**:621-629.
- Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Holtmann GJ, Andrews JM: **Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: An observational cohort prospective study.** *Biopsychosoc Med* 2008, **2**:11.
- Bonicatto S, Dew MA, Soria JJ, Seghezze : **Validity and reliability of symptom checklist '90 (SCL90) in an Argentine population sample.** *Soc Psychiatry Psychiatr Epidemiol* 1997, **32**:332-338.
- Schmitz N, Hartkamp N, Kiuse J, Franke GH, Reister G, Tress W: **The symptom check-list-90-R (SCL-90-R): A German validation study.** *Qual Life Res* 2000, **9**:185-193.
- Binder J, Dobler-Mikola A, Angst J: **An epidemiological study of minor psychiatric disturbances. A field study among 20-year-old females and males in Zurich.** *Soc Psychiatry* 1981, **16**:31-41.
- Buddeberg-Fischer B, Bernet R, Schmid J, Buddeberg C: **Relationship between Disturbed eating behavior and other psychosomatic symptoms in adolescents.** *Psychother Psychosom* 1996, **65**:319-326.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

